AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27475817 — intervention group
Group type: COMPARATOR
Intervention: Physical training only (control)
Number of subjects: 86
Study 27475817 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both operative groups and control)
Number of subjects: 86
Study 23713767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg in fed state
Number of subjects: 32
Study 23713767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin 400 mg in fasted state
Number of subjects: 32
Study 23713767 — intervention group
Group type: COMPARATOR
Intervention: Placebo in fed state
Number of subjects: 32
Study 23713767 — intervention group
Group type: COMPARATOR
Intervention: Placebo in fasted state
Number of subjects: 32
Study 22573670 — intervention group
Group type: EXPERIMENTAL
Intervention: English words with negative valence (e.g., 'violence')
Number of subjects: 0
Study 22573670 — intervention group
Group type: EXPERIMENTAL
Intervention: English words with positive and neutral valence (e.g., 'holiday', 'theory')
Number of subjects: 0
Study 20536509 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (40 g/day)
Number of subjects: 20
Study 20536509 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement (0 g/day)
Number of subjects: 20
Study 18557165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 300 mg
Number of subjects: 386
Study 18557165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg
Number of subjects: 386
Study 18557165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 16307955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentence production experiment in Odawa language
Number of subjects: 0
Study 12214263 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg/Indapamide 0.625 mg
Number of subjects: 500
Study 12214263 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 500
Study 10463514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 263
Study 10463514 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500/125 mg 3 times daily
Number of subjects: 263
Study 8527266 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 9
Study 8527266 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 9
Study 8527266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2562010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluxum (low molecular weight heparin)
Number of subjects: 88
Study 2562010 — intervention group
Group type: COMPARATOR
Intervention: Calcium-heparin
Number of subjects: 88
Study 853979 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent iron sulfate (quick release stick capsule preparation)
Number of subjects: 9
Study 853979 — intervention group
Group type: EXPERIMENTAL
Intervention: trivalent iron citrate complex preparations
Number of subjects: 9
Study 853979 — intervention group
Group type: COMPARATOR
Intervention: ferric iron preparations
Number of subjects: 9
Study 31687831 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet NIV (positive end-expiratory pressure ≥ 10 cm H2O, pressure support = 10-15 cm H2O)
Number of subjects: 15
Study 31687831 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet NIV
Number of subjects: 15
Study 31593855 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim belonging to ingroup
Number of subjects: 202
Study 31593855 — intervention group
Group type: EXPERIMENTAL
Intervention: Victim not belonging to ingroup
Number of subjects: 202
Study 31593855 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait anxiety with victim not belonging to ingroup
Number of subjects: 202
Study 31593855 — intervention group
Group type: EXPERIMENTAL
Intervention: High trait anxiety with victim belonging to ingroup
Number of subjects: 202
Study 29037181 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocryl® (poliglecaprone 25)
Number of subjects: 250
Study 29037181 — intervention group
Group type: COMPARATOR
Intervention: Vicryl Rapide™ (polyglactin 910)
Number of subjects: 250
Study 25926562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-myocardial injections of MSC
Number of subjects: 60
Study 25926562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23096052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 28
Study 23096052 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 28
Study 21763101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group cognitive therapy (IGCT)
Number of subjects: 67
Study 21763101 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 67
Study 21763101 — intervention group
Group type: COMPARATOR
Intervention: Intensive group cognitive therapy (IGCT) and Individual cognitive therapy (ICT)
Number of subjects: 67
Study 19356906 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs
Number of subjects: 22
Study 19356906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16786421 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbryoGlue treatment prior to embryo transfer
Number of subjects: 815
Study 16786421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 815
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetylsalicylate
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular massage
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pentoxifylline
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical beta-blocker
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracentesis of the anterior chamber
Number of subjects: 71
Study 14557172 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 71
Study 11197628 — intervention group
Group type: EXPERIMENTAL
Intervention: C5b-9 immunohistochemical marker
Number of subjects: 2
Study 11197628 — intervention group
Group type: EXPERIMENTAL
Intervention: NP57 immunohistochemical marker
Number of subjects: 2
Study 11197628 — intervention group
Group type: EXPERIMENTAL
Intervention: H&E staining
Number of subjects: 2
Study 8639370 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking reduction advice in combination with dental health instruction and periodontal care
Number of subjects: 98
Study 8639370 — intervention group
Group type: COMPARATOR
Intervention: Dental health instruction only (control)
Number of subjects: 98
Study 1592361 — intervention group
Group type: EXPERIMENTAL
Intervention: idarubicin
Number of subjects: 16
Study 1592361 — intervention group
Group type: EXPERIMENTAL
Intervention: daunorubicin
Number of subjects: 16
Study 6234335 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 4% erythromycin/1.2% zinc acetate solution
Number of subjects: 0
Study 6234335 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-control
Number of subjects: 0
Study 31295391 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 160
Study 31295391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (Er,Cr:YSGG laser device, Waterlase)
Number of subjects: 160
Study 31295391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid treatment [9.6% HF (Pulpdent) for 2 minutes]
Number of subjects: 160
Study 31295391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting (50 µm Al2O3)
Number of subjects: 160
Study 29864437 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial gland ablation with vascular targeted photodynamic therapy
Number of subjects: 413
Study 29864437 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 413
Study 25777270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention (two weekly 1-hour therapy sessions)
Number of subjects: 24
Study 25777270 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (self-monitoring during a similar waitlist period)
Number of subjects: 24
Study 25176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally one hour before surgery and then every 12 hours for the first 24 hours after surgery
Number of subjects: 120
Study 25176361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 120
Study 25176361 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 120
Study 22488231 — intervention group
Group type: COMPARATOR
Intervention: 65 g/L carbohydrate (trial C)
Number of subjects: 12
Study 22488231 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/L carbohydrate and 15 g/L whey protein isolate (trial CP)
Number of subjects: 12
Study 19930146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition colonoscopy (HD)
Number of subjects: 390
Study 19930146 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 390
Study 17517858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous grid‐based vigilance task during exercise
Number of subjects: 10
Study 17517858 — intervention group
Group type: COMPARATOR
Intervention: No vigilance task during exercise
Number of subjects: 10
Study 16124349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime (P2AM)
Number of subjects: 21
Study 16124349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12161513 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone treatment followed by hydrocortisone replacement in elderly subjects with moderate cortisol levels (n = 8)
Number of subjects: 17
Study 12161513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment in elderly subjects with high cortisol levels (n = 9)
Number of subjects: 17
Study 12161513 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone treatment in elderly subjects with high cortisol levels (n = 9)
Number of subjects: 17
Study 10561913 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Number of subjects: 75
Study 10561913 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at 5 microgram(s)/kg/day
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at 7.5 microgram(s)/kg/day
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at 10 microgram(s)/kg/day
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 (all doses combined)
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil recovery
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet recovery
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during IL-3 and chemotherapy
Number of subjects: 20
Study 8558936 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-3 at 10 microgram(s)/kg
Number of subjects: 20
Study 1686250 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (25 μg)
Number of subjects: 23
Study 1686250 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (50 μg)
Number of subjects: 23
Study 1686250 — intervention group
Group type: COMPARATOR
Intervention: CCK-4
Number of subjects: 23
Study 6341045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg three times daily for seven days
Number of subjects: 34
Study 6341045 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 750 mg three times daily for seven days
Number of subjects: 34
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 (Mesangial hypercellularity)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: M0 (No mesangial hypercellularity)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: T1/2 (Tubulointerstitial fibrosis)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: T0 (No tubulointerstitial fibrosis)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: C1/2 (Glomerular crescents)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: E (Endocapillary hypercellularity)
Number of subjects: 162
Study 30453889 — intervention group
Group type: EXPERIMENTAL
Intervention: S (Glomerular segmental sclerosis)
Number of subjects: 162
Study 28904319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight chitosan solution
Number of subjects: 40
Study 28904319 — intervention group
Group type: COMPARATOR
Intervention: Nystatin suspension
Number of subjects: 40
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 5 cm
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 6 cm
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 7 cm
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 5 cm (on second bed)
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 6 cm (on second bed)
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of feedback (TDF) 7 cm (on second bed)
Number of subjects: 19
Study 26298053 — intervention group
Group type: EXPERIMENTAL
Intervention: Duty cycle
Number of subjects: 19
Study 21997672 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck puncture technique
Number of subjects: 59
Study 21997672 — intervention group
Group type: COMPARATOR
Intervention: Femoral head puncture technique
Number of subjects: 59
Study 20175705 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 49
Study 20175705 — intervention group
Group type: COMPARATOR
Intervention: lyophilised urinary hMG (HP‐hMG)
Number of subjects: 49
Study 18317375 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise (20% 1RM)
Number of subjects: 6
Study 18317375 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance exercise with blood flow restriction (REFR)
Number of subjects: 6
Study 16680252 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (10 mg x kg(‐1))
Number of subjects: 105
Study 15732235 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 116
Study 15732235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 10862158 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg qd)
Number of subjects: 13
Study 10862158 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 13
Study 10862158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9322569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral thiamine (10 mg/d)
Number of subjects: 222
Study 9322569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 8383578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin at 1 g/day
Number of subjects: 303
Study 8383578 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 303
Study 3956939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (during the experiment)
Number of subjects: 37
Study 3956939 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (not smoking)
Number of subjects: 37
Study 3956939 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 37
Study 3046351 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated cuff
Number of subjects: 234
Study 3046351 — intervention group
Group type: COMPARATOR
Intervention: Control (without cuff)
Number of subjects: 234
Study 30616698 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Number of subjects: 50
Study 30616698 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for Alcohol Problems (CAP)
Number of subjects: 50
Study 29376886 — intervention group
Group type: EXPERIMENTAL
Intervention: scalp acupuncture + low frequency rTMS + routine rehabilitation treatment
Number of subjects: 28
Study 29376886 — intervention group
Group type: COMPARATOR
Intervention: scalp acupuncture + routine rehabilitation treatment
Number of subjects: 28
Study 26803187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) and Concomitant Chemotherapy (CCT)
Number of subjects: 117
Study 25693890 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (25 g)
Number of subjects: 0
Study 25693890 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-sweetened control drink
Number of subjects: 0
Study 23284151 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful smoking cessation
Number of subjects: 491
Study 23284151 — intervention group
Group type: COMPARATOR
Intervention: Relapse to smoking
Number of subjects: 491
Study 20533761 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine/montelukast (10 mg/10 mg)
Number of subjects: 0
Study 20533761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18781853 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 carriers
Number of subjects: 237
Study 18781853 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype and nongenetic risk factors (age >65 years, Type 2 diabetes mellitus, decreased left ventricular function, renal failure, acute coronary syndrome)
Number of subjects: 237
Study 18781853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongenetic factors
Number of subjects: 237
Study 18781853 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 genotype
Number of subjects: 237
Study 16755268 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 measurements of biomarkers
Number of subjects: 206
Study 16755268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 measurement of biomarkers
Number of subjects: 206
Study 16755268 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or 4 measures of biomarkers
Number of subjects: 206
Study 16755268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 measurement of ascorbic acid and malondialdehyde
Number of subjects: 206
Study 15307693 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Huoxue Tongfu (YYHT) principle
Number of subjects: 40
Study 15307693 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (Control)
Number of subjects: 40
Study 11297959 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg daily elemental zinc)
Number of subjects: 420
Study 11297959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 9052564 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 100
Study 9052564 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 100
Study 7509243 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (1 to 10 mg once daily for 24 weeks)
Number of subjects: 160
Study 7509243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 24 weeks)
Number of subjects: 160
Study 3080693 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH 150 mg subcutaneous injection
Number of subjects: 12
Study 3080693 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH 500 mg IV infusion
Number of subjects: 12
Study 3080693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31898118 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA + coaching
Number of subjects: 411
Study 31898118 — intervention group
Group type: COMPARATOR
Intervention: HRA‐alone
Number of subjects: 411
Study 29987899 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MS)
Number of subjects: 217
Study 29987899 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (MS) plus avanafil
Number of subjects: 217
Study 29987899 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil
Number of subjects: 217
Study 29987899 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine
Number of subjects: 217
Study 29987899 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group E)
Number of subjects: 217
Study 27133819 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and chemotherapy (CHT)
Number of subjects: 184
Study 27133819 — intervention group
Group type: COMPARATOR
Intervention: ATRA and arsenic trioxide (ATO)
Number of subjects: 184
Study 27133819 — intervention group
Group type: COMPARATOR
Intervention: FLT3-ITD positive patients receiving ATRA-CHT
Number of subjects: 184
Study 27133819 — intervention group
Group type: COMPARATOR
Intervention: FLT3-ITD mutations in patients receiving ATRA-ATO
Number of subjects: 184
Study 24497338 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 201
Study 24497338 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic Drugs (AAD)
Number of subjects: 201
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Avilamycin (44 mg/kg)
Number of subjects: 750
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Rosemary essential oil (100 mg/kg)
Number of subjects: 750
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Oregano essential oil (100 mg/kg)
Number of subjects: 750
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Rosemary and oregano essential oils (50 mg each/kg)
Number of subjects: 750
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Commercial blend of essential oils (1,000 mg/kg)
Number of subjects: 750
Study 22064737 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CON)
Number of subjects: 750
Study 20472590 — intervention group
Group type: EXPERIMENTAL
Intervention: Early season skim milk
Number of subjects: 16